 Results from the phase 2 CATALINA study using NGM621 for the treatment of patients with Geographic Atrophy are expected in the 2nd half of 2022. Results from a phase 12 study using NGM707 for the treatment of patients with advanced cancer are expected in the 2nd half of 2022. 